Bruker
BRKR

$66.81

4.02%

Market Cap: 10.1B

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Employees: 9,707

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

0

News positive %

of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,475% more call options, than puts

Call options by funds: $22.8M | Put options by funds: $1.45M

100% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 6 (+3) [Q1 2024]

51% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 45

28% more capital invested

Capital invested by funds: $8.04B [Q4 2023] → $10.3B (+$2.26B) [Q1 2024]

21% more repeat investments, than reductions

Existing positions increased: 146 | Existing positions reduced: 121

7% more funds holding

Funds holding: 352 [Q4 2023] → 375 (+23) [Q1 2024]

0.6% more ownership

Funds ownership: 79.06% [Q4 2023] → 79.65% (+0.6%) [Q1 2024]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$60

10%

downside

Avg. target

$84

26%

upside

High target

$102

53%

upside

10 analyst ratings

6 positive

60%

2 neutral

20%

2 negative

20%

Citigroup Patrick Donnelly	20%upside $80	Buy Maintained	10 Jul 2024
Goldman Sachs Matthew Sykes	10%downside $60	Sell Maintained	9 Jul 2024
Stifel Daniel Arias	15%upside $77	Hold Maintained	20 May 2024
B of A Securities Derik De Bruin	35%upside $90	Buy Maintained	20 May 2024
Goldman Sachs Matthew Sykes	11%upside $74	Sell Maintained	10 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about BRKR published over the past 30 days

Zacks Investment Research

Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Bruker Announces that Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher Regional Court, in order to suspend an injunction that had been impacting sales of CosMx™ Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This development is connected with ongoing patent litigation with 10x Genomics, during an appeal process in Germany. Effective immediately, all CosMx products are once again available.

Bruker Announces that Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately

7 Quantum Computing Stocks That Could Be Multibaggers in the Making: July Edition

Quantum computing is still relatively new which means that there is a lot of opportunity when it comes to quantum computing stocks. Advancements in quantum computing technology such as the superconducting qubits and the trapped ion technology have boosted the efficiency and effectiveness of quantum systems.

7 Quantum Computing Stocks That Could Be Multibaggers in the Making: July Edition

Zacks Investment Research

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

Zacks Investment Research

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin

BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research. Ultra-high field NMR is a vital tool in pharmacology research, providing unique in.

Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin

Zacks Investment Research

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich

Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things.

Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich

Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection

BOSTON--(BUSINESS WIRE)--Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis today announced that it is collaborating with Bruker BioAFM, a business unit of Bruker (Nasdaq: BRKR), to develop the world's first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning. Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is.

Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection

See News Rankings